Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QGEN Stock Forecast 2025-2026
$47.01
Current Price
$10.19B
Market Cap
Buy 7
Hold 9
Sell 0
Wall St Analyst Ratings
Distance to QGEN Price Targets
+21.3%
To High Target of $57.00
+8.5%
To Median Target of $51.00
-4.3%
To Low Target of $45.00
QGEN Price Momentum
-1.5%
1 Week Change
+9.2%
1 Month Change
+8.3%
1 Year Change
+5.6%
Year-to-Date Change
-9.4%
From 52W High of $51.88
+24.9%
From 52W Low of $37.63
📊 TOP ANALYST CALLS
Did QGEN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if QIAGEN is one of their latest high-conviction picks.
Latest QGEN Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, QGEN has a neutral consensus with a median price target of $51.00 (ranging from $45.00 to $57.00). The overall analyst rating is N/A (N/A/10). Currently trading at $47.01, the median forecast implies a 8.5% upside. This outlook is supported by 7 Buy, 9 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Daniel Arias at Stifel, suggesting a 4.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QGEN Analyst Ratings
7
Buy
9
Hold
0
Sell
QGEN Price Target Range
Low
$45.00
Average
$51.00
High
$57.00
Current: $47.01
Latest QGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 2, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $53.00 |
| Aug 7, 2025 | UBS | John Sourbeer | Neutral | Maintains | $50.00 |
| Jun 26, 2025 | B of A Securities | Derik De Bruin | Buy | Maintains | $53.00 |
| Jun 24, 2025 | Barclays | Luke Sergott | Overweight | Initiates | $55.00 |
| Apr 21, 2025 | Baird | Catherine Schulte | Neutral | Maintains | $43.00 |
| Apr 4, 2025 | Redburn Atlantic | Ed Ridley-Day | Neutral | Downgrade | $N/A |
| Feb 19, 2025 | Baird | Catherine Schulte | Neutral | Downgrade | $42.00 |
| Feb 7, 2025 | UBS | John Sourbeer | Neutral | Maintains | $48.00 |
| Jan 6, 2025 | Morgan Stanley | Steve Beuchaw | Equal-Weight | Downgrade | $48.00 |
| Dec 10, 2024 | Jefferies | Tycho Peterson | Buy | Upgrade | $54.00 |
| Oct 17, 2024 | HSBC | Shubhangi Gupta | Hold | Downgrade | $N/A |
| Aug 2, 2024 | Baird | Catherine Schulte | Outperform | Maintains | $52.00 |
| Jun 27, 2024 | Wolfe Research | Doug Schenkel | Outperform | Upgrade | $50.00 |
| Jun 18, 2024 | JP Morgan | Casey Woodring | Overweight | Maintains | $54.00 |
| May 1, 2024 | Stifel | Daniel Arias | Hold | Maintains | $45.00 |
| Feb 16, 2024 | Morgan Stanley | Steve Beuchaw | Overweight | Upgrade | $51.00 |
| Feb 8, 2024 | JP Morgan | Tycho Peterson | Overweight | Maintains | $52.00 |
| Feb 8, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $60.00 |
| Dec 20, 2023 | JP Morgan | Tycho Peterson | Overweight | Maintains | $50.00 |
| Dec 19, 2023 | Wells Fargo | Timothy Daley | Equal-Weight | Initiates | $44.00 |
Qiagen N.V. (QGEN) Competitors
The following stocks are similar to QIAGEN based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Qiagen N.V. (QGEN) Financial Data
Qiagen N.V. has a market capitalization of $10.19B with a P/E ratio of 25.4x. The company generates $2.07B in trailing twelve-month revenue with a 19.6% profit margin.
Revenue growth is +6.1% quarter-over-quarter, while maintaining an operating margin of +25.8% and return on equity of +11.3%.
Valuation Metrics
Market Cap
$10.19B
Enterprise Value
$10.66B
P/E Ratio
25.4x
PEG Ratio
0.8x
Price/Sales
4.9x
Growth & Margins
Revenue Growth (YoY)
+6.1%
Gross Margin
+62.2%
Operating Margin
+25.8%
Net Margin
+19.6%
EPS Growth
+32.6%
Financial Health
Cash/Price Ratio
+16.6%
Current Ratio
2.6x
Debt/Equity
59.1x
ROE
+11.3%
ROA
+8.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Qiagen N.V. (QGEN) Business Model
About Qiagen N.V.
What They Do
Develops molecular diagnostics and sample preparation technologies.
Business Model
The company operates by offering a wide range of products and solutions for molecular diagnostics and sample preparation, generating revenue through the sale of consumables, automated instruments, and bioinformatics software. Its customer base includes researchers, clinical laboratories, and pharmaceutical companies, which utilize Qiagen's products for applications in molecular biology and disease detection.
Additional Information
Qiagen has established a strong presence in healthcare and academic research sectors, particularly in infectious disease diagnostics, including COVID-19 testing. As a public company listed on various global stock indices, its performance reflects its significance in the biotechnology and healthcare markets.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
5,700
CEO
Mr. Thierry Bernard
Country
Netherlands
IPO Year
1996
Website
www.qiagen.comQiagen N.V. (QGEN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Qiagen (QGEN) Up 6.3% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dec 04, 2025
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Qiagen N.V. (QGEN) participated in the Citi Annual Global Healthcare Conference, presenting updates on its business and future outlook. Further details are available in the conference transcript.
Why It Matters
Qiagen's presentation at a major healthcare conference could signal potential growth opportunities, new partnerships, or product developments, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Qiagen N.V. (QGEN) participated in the Evercore 8th Annual Healthcare Conference, discussing its business and strategies. Further details can be found in the conference transcript.
Why It Matters
Qiagen's presentation at a major healthcare conference can signal new developments or strategies, influencing investor sentiment and potential stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Qiagen N.V. is hosting a "Deep Dive" event focusing on its sample technologies, with presentations from key executives, including CEO Thierry Bernard. The event aims to discuss leadership, innovation, and future expansion.
Why It Matters
Qiagen's focus on leadership and innovation in sample technologies signals potential growth and competitive advantage, impacting future revenue and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
CellBxHealth strikes co-marketing deal with Qiagen to widen use of Parsortix cancer platform
18 days ago
Quick Summary
CelLBxHealth PLC partnered with Qiagen in a collaboration and co-marketing deal to promote its Parsortix system for drugmakers, enhancing projects in circulating tumor cell research and diagnostics.
Why It Matters
The collaboration with Qiagen enhances CelLBxHealth's market reach and potential revenue streams, positioning it favorably in the growing diagnostics sector for cancer research.
Source: Proactive Investors
Market Sentiment:
Positive
CellBxHealth rises on Qiagen tie-up to push Parsortix into more drug-development projects
18 days ago
Quick Summary
CelLBxHealth PLC shares rose 7% to 1.93p following a collaboration with Qiagen to expand its Parsortix platform for pharmaceutical partnerships, integrating it with Qiagen's technologies.
Why It Matters
The 7% rise in CelLBxHealth shares reflects positive market sentiment following their collaboration with Qiagen, which enhances growth potential and expands their technology's market reach.
Source: Proactive Investors
Market Sentiment:
Positive
Qiagen N.V. (QGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
19 days ago
Quick Summary
Qiagen N.V. will participate in the 7th Annual Wolfe Research Healthcare Conference on November 17, 2025, at 12:40 PM EST, featuring CEO Thierry Bernard.
Why It Matters
Qiagen's participation in a prominent healthcare conference indicates potential insights into its strategy and performance, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About QGEN Stock
What is Qiagen N.V.'s (QGEN) stock forecast for 2026?
Based on our analysis of 19 Wall Street analysts, Qiagen N.V. (QGEN) has a median price target of $51.00. The highest price target is $57.00 and the lowest is $45.00.
Is QGEN stock a good investment in 2026?
According to current analyst ratings, QGEN has 7 Buy ratings, 9 Hold ratings, and 0 Sell ratings. The stock is currently trading at $47.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QGEN stock?
Wall Street analysts predict QGEN stock could reach $51.00 in the next 12 months. This represents a 8.5% increase from the current price of $47.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Qiagen N.V.'s business model?
The company operates by offering a wide range of products and solutions for molecular diagnostics and sample preparation, generating revenue through the sale of consumables, automated instruments, and bioinformatics software. Its customer base includes researchers, clinical laboratories, and pharmaceutical companies, which utilize Qiagen's products for applications in molecular biology and disease detection.
What is the highest forecasted price for QGEN Qiagen N.V.?
The highest price target for QGEN is $57.00 from at , which represents a 21.3% increase from the current price of $47.01.
What is the lowest forecasted price for QGEN Qiagen N.V.?
The lowest price target for QGEN is $45.00 from Daniel Arias at Stifel, which represents a -4.3% decrease from the current price of $47.01.
What is the overall QGEN consensus from analysts for Qiagen N.V.?
The overall analyst consensus for QGEN is neutral. Out of 19 Wall Street analysts, 7 rate it as Buy, 9 as Hold, and 0 as Sell, with a median price target of $51.00.
How accurate are QGEN stock price projections?
Stock price projections, including those for Qiagen N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 6, 2025 12:36 PM UTC